Evidence map›Paper›PMID 41392710›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025

Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference.

Emma Svennberg, Jose Luis Merino, Jason Andrade, Matteo Anselmino, Elena Arbelo, Eric Boersma, Giuseppe Boriani, Günter Breithardt, Mina Chung, Janice Chyou and 51 more

Erratum issuedAbstract readConsensus Statement
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Intracardiac Echocardiography during Invasive Electrophysiological Procedures: a Scientific Statement of the European Heart Rhythm Association of the ESC, and the European Association of Percutaneous Cardiovascular Interventions of the ESC.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Guideline
  2. Alcohol consumption and risk of atrial fibrillation: a pairwise and network meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Pooled it
  3. Interactions of blood biomolecules with early rhythm control in atrial fibrillation patients: exploratory analysis of the EAST-AFNET 4 biomolecule study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  4. Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2026
    Article
  5. Left atrial anatomy and atrial arrhythmia recurrence after pulsed-field ablation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  6. Essential antiarrhythmic drug accessibility worldwide: a multi-survey study and comprehensive evaluation of access and supply challenges.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  7. Review
  8. Article
  9. Smartphone app-based symptom assessment in patients with atrial fibrillation on the waiting list for electrical cardioversion: a TeleConvert-atrial fibrillation sub analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  10. Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  11. Artificial intelligence for patient selection in pulsed-field ablation: promise, pragmatism, and the need for standards.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  12. Comprehensive assessment of novel cardiovascular biomarkers in AF.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  13. Review
  14. Cryptogenic stroke in women: impact of insertable cardiac monitoring in the STROKEWISE cohort study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  15. Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation: NOAH-AFNET 6.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  16. Cardiovascular-kidney-metabolic interplay in patients with atrial fibrillation receiving direct oral anticoagulants.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

61 authors.

Emma SvennbergDepartment of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-6413-0870
Jose Luis MerinoDepartment of Cardiology, La Paz University Hospital, IDIPaz, Universidad Autonoma, Madrid, Spain.ORCID 0000-0002-1737-1903
Jason AndradeVancouver General Hospital, Vancouver, Canada.ORCID 0000-0002-8493-5123
Matteo AnselminoDivision of Cardiology, Cardiovascular and Thoracic Department, Department of Medical Sciences, Città della Salute e della Scienza di Torino Hospital, University of Turin, Turin, Italy.ORCID 0000-0002-6311-4270
Elena ArbeloArrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-0424-6393
Eric BoersmaDepartment of Cardiology, Cardiovascular Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-2559-7128
Giuseppe BorianiCardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.ORCID 0000-0002-9820-4815
Günter BreithardtDepartment of Cardiovascular Medicine, University Hospital, Münster, Germany.ORCID 0000-0001-7574-8900
Mina ChungCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-7835-6045
Janice ChyouMount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-2990-8122
Ariel CohenService de Cardiologie, AP-HP-Hôpital Saint-Antoine and Hôpital Tenon, 184, Rue du Faubourg Saint Antoine, Paris Cedex 12, France.ORCID 0000-0003-1027-0787
Jens Cosedis NielsenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-0631-0010
Wolfgang DichtlDepartment of Internal Medicine III (Cardiology and Angiology), Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0002-0421-2110
Søren Zöga DiederichsenDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-9687-0857
Dobromir DobrevInstitute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-4612-117X
Wolfram DoehnerBIH Center for Regenerative Therapies and Deutsches Herzzentrum der Charité-Virchow Klinikum, Charité-Universitätsmedizin Berlin, German Centre for Cardiovascular Research Partner Site Berlin, Berlin, Germany.ORCID 0000-0001-7598-708X
Elke DworatzekPfizer Pharma GmbH, Berlin, Germany.
Larissa FabritzAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0002-9241-1733
David Filgueiras-RamaCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.ORCID 0000-0001-5909-2454
Claudio GimpelewiczNovartis Pharma AG, Basel, Switzerland.ORCID 0000-0001-8700-0641
Guido HackBristol Myers Squibb, Munich, Germany.ORCID 0009-0005-5315-5430
Stéphane HatemSorbonne University, Institute of Cardiometabolism and Nutrition, IHU ICAN, INSERM UMR_S1166, Pitié-Salpêtrière Hospital, Paris, France.ORCID 0000-0002-9790-0755
Jeff HealeyPopulation Health Research Institute, Hamilton, Ontario, Canada.ORCID 0000-0003-1216-7580
Hein HeidbuchelDepartment of Cardiology, Antwerp University Hospital, Antwerp, Belgium.ORCID 0000-0001-9301-8127
Ziad HijaziDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-7420-743X
Anders Gaarsdal HolstAcesion Pharma, Nordre Fasanvej 215, Frederiksberg 2000, Denmark.ORCID 0000-0002-5343-7367
Leif Hove-MadsenInstituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), Barcelona, Spain.ORCID 0000-0001-5493-3998
Jose JalifeCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.ORCID 0000-0003-0080-3500
Roderick van LeerdamRoyal Philips, Amsterdam, The Netherlands.ORCID 0000-0002-6785-5463
Dominik LinzDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.ORCID 0000-0003-4893-0824
Gregory Y H LipLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.ORCID 0000-0002-7566-1626
Steven LubitzNovartis Biomedical Research, Basel, Switzerland.ORCID 0000-0002-9599-4866
Mirko de MelisBakken Research Center, Maastricht, The Netherlands.ORCID 0000-0002-9223-4183
Ralf MeyerMedtronic, Muenster, Germany.ORCID 0000-0002-4878-2879
Michal OrczykowskiArrhythmia Department, National Institute of Cardiology, Warsaw, Poland.ORCID 0000-0003-2194-9648
Abdul Shokor ParwaniDepartment of Cardiology, Deutsches Herzzentrum Charité, Berlin, Germany.ORCID 0000-0003-2043-7050
Andreu Porta-SanchezSecció d'Arrítmies, Servei de Cardiologia, ICCV Hospital Clínic de Barcelona, Laboratori de Biopatologia i Tractament de les Arrítmies, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-3510-1488
Tom de PotterCardiovascular Center, AZORG, Aalst, Belgium.ORCID 0000-0003-1424-114X
Ursula RavensAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0003-3813-3127
Michiel RienstraDepartment of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-2581-070X
Andreas RilligPfizer Pharma GmbH, Berlin, Germany.ORCID 0000-0003-3457-0936
Lena RivardInstitute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-1340-0850
Daniel ScherrDivision of Cardiology, Medical University of Graz, Austria.ORCID 0000-0001-5868-5493
Renate B SchnabelAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0001-7170-9509
Ulrich SchottenAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0003-1532-3315
Stefan SimovicDepartment of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Serbia.ORCID 0000-0003-0911-2028
Moritz SinnerAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0002-6660-796X
Christian SohnsDepartment of Electrophysiology, Heart- and Diabetes Center NRW, Bad Oeynhausen, Germany.ORCID 0000-0003-0490-5862
Philipp SommerDepartment of Electrophysiology, Heart- and Diabetes Center NRW, Bad Oeynhausen, Germany.ORCID 0000-0002-3037-8704
Gerhard SteinbeckAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0001-6010-941X
Daniel StevenAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0001-6839-5895
Arian SultanSt. Georg Heart Center Hamburg, Germany.ORCID 0000-0003-1807-4860
Goetz ThomallaDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-4785-1449
Tobias ToennisUniversity Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-7351-0621
Stylianos TzeisDepartment of Cardiology, Mitera Hospital, Athens, Greece.ORCID 0000-0002-2007-1928
Niels VoigtInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Germany.ORCID 0000-0001-8230-2341
Manish WadhwaMedical Office, Philips Ambulatory Monitoring and Diagnostics, San Diego, CA, USA.ORCID 0009-0003-3366-5623
Reza WakiliAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0002-6326-1537
Henning WittPfizer Pharma GmbH, Berlin, Germany.ORCID 0000-0001-6256-3763
Andreas GoetteAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0002-8223-7209
Paulus KirchhofAtrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Münster, Germany.ORCID 0000-0002-1881-0197

Funding

Accelerating Clinical Trials funding stream in CanadaDutch Heart FoundationElse Kroner-Fresenius FoundationEuropean Union 965286German Center for Cardiovascular ResearchGerman Ministry of Education and Research 81X2800182German Ministry of Education and Research 81Z0710110German Ministry of Education and Research 81Z0710116German Research Foundation 509167694German Research Foundation 535121142German Research Foundation 564997921
6 · The paper itself

Abstract

Atrial fibrillation (AF) is a growing unmet medical need. To reduce its impact on patients' lives, improvements in stroke prevention therapy, treatment of concomitant conditions, and rhythm control therapy are actively developed: Innovations in anti-thrombotic agents, new anti-arrhythmic drugs (AADs), and novel interventional rhythm control therapies emerge alongside AF-reducing effects of general cardiometabolic therapies. Simple risk scores are slowly replaced by personalized AF risk estimation using quantifiable features. These developments were discussed by over 80 experts from academia and industry during the 10th Atrial Fibrillation NETwork /European Heart Rhythm Association consensus conference from 5 to 7 May 2025. The emerging consensus, described here, is multi-domain therapy combining stroke prevention, rhythm control, and therapy of concomitant cardiovascular conditions. This combines anti-coagulants, AADs, and AF ablation with old and new cardiometabolic drugs that can reduce AF risk, AF burden, and AF-related complications at scale. The paper furthermore describes quantitative traits that may enable a shift towards risk-driven therapy based on AF phenotypes. These can enable adjusted therapy strategies that are safe, accessible, and patient-centred. Applying modern data science and artificial intelligence methods to quantitative phenotypic and genetic features can further improve risk estimation and personalized therapy selection. At the same time, translational and clinical research into reversing the drivers of AF and into improved stroke prevention through new drugs and through combination therapies is needed. Together, these efforts offer pathways towards personalized, patient-centred, multi-modal, and accessible AF management that integrates rhythm control, stroke prevention, and therapy of concomitant conditions to bridge today's practical needs with tomorrow's therapeutic innovation.

Indexed as

Anti-Arrhythmia AgentsAtrial FibrillationCatheter AblationStrokeAnticoagulantsComorbidityHumansRisk AssessmentRisk FactorsAnti-Arrhythmia AgentsAnticoagulantsAblationAntiarrhythmic drugsArtificial intelligenceAtrial fibrillationAtrial fibrillation burdenHeart failureIntegrated careRhythm controlStroke prevention

Identifiers

PMID41392710
PMCPMC12741663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.